GB202009069D0 - Process - Google Patents

Process

Info

Publication number
GB202009069D0
GB202009069D0 GBGB2009069.2A GB202009069A GB202009069D0 GB 202009069 D0 GB202009069 D0 GB 202009069D0 GB 202009069 A GB202009069 A GB 202009069A GB 202009069 D0 GB202009069 D0 GB 202009069D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2009069.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Z Factor Ltd
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Priority to GBGB2009069.2A priority Critical patent/GB202009069D0/en
Publication of GB202009069D0 publication Critical patent/GB202009069D0/en
Priority to PCT/GB2021/051488 priority patent/WO2021255429A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2009069.2A 2020-06-15 2020-06-15 Process Ceased GB202009069D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2009069.2A GB202009069D0 (en) 2020-06-15 2020-06-15 Process
PCT/GB2021/051488 WO2021255429A1 (en) 2020-06-15 2021-06-15 Process for preparing n,n-dimethyl-4-((6-oxopyrimidin-1(6h)-yl)methyl)benzamide from 4-((6-oxopyrimidin-1(6h)-yl)methyl)benzoic acid, and crystalline forms of the benzamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2009069.2A GB202009069D0 (en) 2020-06-15 2020-06-15 Process

Publications (1)

Publication Number Publication Date
GB202009069D0 true GB202009069D0 (en) 2020-07-29

Family

ID=71835598

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2009069.2A Ceased GB202009069D0 (en) 2020-06-15 2020-06-15 Process

Country Status (2)

Country Link
GB (1) GB202009069D0 (en)
WO (1) WO2021255429A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency

Also Published As

Publication number Publication date
WO2021255429A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
GB202005468D0 (en) Enzyme-media process
GB202005217D0 (en) Process
GB202108985D0 (en) Process
GB202013383D0 (en) Process
GB202007980D0 (en) Process
GB202110568D0 (en) Process
GB202104958D0 (en) Process
GB202020054D0 (en) Process
GB202009069D0 (en) Process
GB202002417D0 (en) Process
GB202001226D0 (en) Process
GB202117726D0 (en) Process
GB202117617D0 (en) Process
GB202117202D0 (en) Process
GB202116895D0 (en) Process
GB202116403D0 (en) Process
GB202112701D0 (en) Process
GB202112262D0 (en) Process
GB202111777D0 (en) Process
GB202111595D0 (en) Process
GB202107443D0 (en) Process
GB202104944D0 (en) Process
GB202104681D0 (en) Process
GB202104080D0 (en) Process
GB202104079D0 (en) Process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)